Basic Information
| LncRNA/CircRNA Name | PXN-AS1-L |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | qPCR |
| Sample | glioma tissues |
| Expression Pattern | up-regulated |
| Function Description | PXN-AS1-L levels were differentially upregulated in glioma specimens compared with paired non-tumor specimens. Higher levels of PXN-AS1-L in glioma were observed to be positively associated with WHO grade , KPS and tumor recurrence. Survival assays revealed that glioma patients with higher PXN-AS1-L expressions had worse overall survival rates. |
| Pubmed ID | 31696482 |
| Year | 2019 |
| Title | Up-regulation of lncRNA PXN-AS1-L Is Associated With Unfavorable Prognosis in Patients Suffering From Glioma |
External Links
| Links for PXN-AS1-L | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |